Saccharomyces boulardii for Clostridium difficile‐Associated Enteropathies in Infants
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Based on experimental evidence in animals showing that the oral administration of Saccharomyces boulardii is effective in reducing morbidity and mortality due to Clostridium difficile‐induced pseudomembranous colitis, we conducted an open trial to examine the effects of the living yeast, given as primary therapy, in a selected group of infants and children with persistent intestinal symptoms related to toxinogenic C. difficile overgrowth. Over a period of 10 consecutive months, we studied 19 eligible patients (median age 8 months) who presented with enteral symptoms lasting for > 15 days and who had solely C. difficile in stools with positive cytotoxin B assay. Serotyping of the strains and determination in vitro of production of toxins A and B were performed subsequently. The patients presented with persistent or protracted diarrhea, malabsorption, and failure to grow (n = 8), or with repeated attacks of colics, emesis, and hypermeteorism without diarrhea (n = 4), or with both entities (n = 7). Patients with chronic protracted diarrhea (n = 3) had‐depressed jejunal disaecharidase activities and ultrastructural changes of enterocytes, including sparce and shortened microvilli. None had evidence of colitis. All the strains of C. difficile tested (n = 17) belonged to pathogenic serotypes (A 1, A 8, C, F, G, H, and K) and produced in vitro high levels of toxins A (n = 16) and B (n = 17). S. boulardii was given orally in a lyophilized form over 15 days (250 mg two to four times per day according to age). Within 1 week of treatment, enteral symptoms and physical findings resolved in 18 patients (95%) with marked decreases (p < 0.001) in the number of stools, frequency of colic episodes, and total duration of colics per day. Clearing of toxin B was observed within 15 days of therapy in 16 cases (85%), whereas eradication of C. difficile from stools was complete after 1 month in 14 (73%). Also, the ultrastructural changes observed in patients with chronic protracted diarrhea (n = 3) had disappeared after 1 month. A clinical and bacteriological relapse occurred in two patients (11%), which resolved rapidly with a second 15‐day course of S. boulardii. These findings suggest that some toxinogenic strains of C. difficile may cause chronic enteropathies without colitis that may be improved by oral administration of S. boulardii.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374 · cited 1×
“– 2/6 In adults, Clostridium difficile is now recognized as the principal etiological agent of pseudomembranous colitis and of antibiotic-associated diarrhea (1).”
Background
Cited by
Probiotic bacteria: safety, functional and technological properties
Saarela, M., Mogensen, G., Fondén, R., Mättö, J., & Mattila-Sandholm, T. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(00)00375-8 · Cited by 1,202
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis
D'Souza, A. L., Rajkumar, C., Cooke, J., & Bulpitt, C. J. (2002) · BMJ · doi:10.1136/bmj.324.7350.1361 · Cited by 664
Protection from gastrointestinal diseases with the use of probiotics
Marteau, P. R., Vrese, M. D., Cellier, C. J., & Schrezenmeir, J. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.430s · Cited by 596
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
McFarland, L. V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i18.2202 · Cited by 545
Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/318130 · Cited by 529
Metadata
- Authors
- Buts, J., Corthier, G., & Delmee, M.
- Venue
- Journal of Pediatric Gastroenterology and Nutrition
- Publisher
- Wiley
- Published
- 1993-05
- Volume
- 16
- Issue
- 4
- Pages
- 419-425
- ISSN
- 0277-2116 (ISSN-L)
- 1536-4801
- OpenAlex
- W1990824345
- Cited by
- 135
- References
- 1
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Saccharomyces boulardii for Clostridium difficile‐Associated Enteropathies in Infants. https://app.cochat.ai/papers/10.1002/j.1536-4801.1993.tb10889.x
- The paper
- Buts, J., Corthier, G., & Delmee, M. (1993). Saccharomyces boulardii for Clostridium difficile‐Associated Enteropathies in Infants. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/j.1536-4801.1993.tb10889.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.